Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Input metadata references "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: September 26, 2018
Event: Regulation FD Disclosure regarding participation in the 16th Annual Discovery on Target Conference in Boston, Massachusetts.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a conference presentation and does not contain financial statements or operational metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing serves solely to disclose the presentation of a conference poster (Exhibit 99.1).
Guidance, Outlook, and Risks
Management Commentary: The company disclosed the presentation of a poster at a scientific conference. The content of the poster is attached as Exhibit 99.1.
Legal Status of Information: The information in Item 7.01 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Key Facts for Investor Verification
- Verify the scientific data and conclusions presented in the conference poster (Exhibit 99.1) attached to this filing.
- Confirm the registrant's name is RXi Pharmaceuticals Corporation, distinct from the metadata reference to Phio Pharmaceuticals Corp.
- Note that the conference information is not legally "filed" for liability purposes under Section 18 of the Exchange Act.
- Review subsequent filings (e.g., 10-Q or 10-K) for actual financial performance data, as this 8-K contains none.